Review



scc15 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC scc15 cells
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Scc15 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 706 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scc15 cells/product/ATCC
    Average 96 stars, based on 706 article reviews
    scc15 cells - by Bioz Stars, 2026-04
    96/100 stars

    Images

    1) Product Images from "METTL5-mediated m6A modification of 18S rRNA drives oral squamous cell carcinoma progression by enhancing CCND3 translation"

    Article Title: METTL5-mediated m6A modification of 18S rRNA drives oral squamous cell carcinoma progression by enhancing CCND3 translation

    Journal: Oncology Letters

    doi: 10.3892/ol.2026.15490

    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, SCC15) and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Figure Legend Snippet: METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, SCC15) and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.

    Techniques Used: Comparison, Expressing, Western Blot

    Knockout of METTL5 inhibits the progression of OSCC in vitro . (A) Validation of METTL5 stable knockout in SCC15 cells by western blotting. Results of (B) Cell Counting Kit-8 assay, (C) colony formation assay, (D) Transwell assay and (E) wound healing assay after knockout of METTL5 in SCC15 cells. *P<0.05, **P<0.01; ***P<0.001; ****P<0.0001. METTL5, methyltransferase 5, N6-adenosine; NC, negative control; OSCC, oral squamous cell carcinoma; sg, small guide RNA; NC, negative control; OD, optical density.
    Figure Legend Snippet: Knockout of METTL5 inhibits the progression of OSCC in vitro . (A) Validation of METTL5 stable knockout in SCC15 cells by western blotting. Results of (B) Cell Counting Kit-8 assay, (C) colony formation assay, (D) Transwell assay and (E) wound healing assay after knockout of METTL5 in SCC15 cells. *P<0.05, **P<0.01; ***P<0.001; ****P<0.0001. METTL5, methyltransferase 5, N6-adenosine; NC, negative control; OSCC, oral squamous cell carcinoma; sg, small guide RNA; NC, negative control; OD, optical density.

    Techniques Used: Knock-Out, In Vitro, Biomarker Discovery, Western Blot, Cell Counting, Colony Assay, Transwell Assay, Wound Healing Assay, Negative Control

    Overexpression of METTL5 promotes the progression of OSCC. (A) Validation of METTL5 overexpression in SCC15 cells by western blotting. (B) Results of the Cell Counting Kit-8 assay after METTL5 overexpression in SCC15 cells. (C) Statistical results of the Transwell assay after METTL5 overexpression in SCC15 cells. (D) Results of the colony formation assay after knockout of METTL5 in SCC15 cells. **P<0.01. METTL5, methyltransferase 5, N6-adenosine; OSCC, oral squamous cell carcinoma; oe, overexpression; NC, negative control; OD, optical density.
    Figure Legend Snippet: Overexpression of METTL5 promotes the progression of OSCC. (A) Validation of METTL5 overexpression in SCC15 cells by western blotting. (B) Results of the Cell Counting Kit-8 assay after METTL5 overexpression in SCC15 cells. (C) Statistical results of the Transwell assay after METTL5 overexpression in SCC15 cells. (D) Results of the colony formation assay after knockout of METTL5 in SCC15 cells. **P<0.01. METTL5, methyltransferase 5, N6-adenosine; OSCC, oral squamous cell carcinoma; oe, overexpression; NC, negative control; OD, optical density.

    Techniques Used: Over Expression, Biomarker Discovery, Western Blot, Cell Counting, Transwell Assay, Colony Assay, Knock-Out, Negative Control

    Inhibition of METTL5 suppresses tumor growth in vivo . (A) Representative images of subcutaneous tumors from the SCC15 cell mouse model. (B) Quantification of tumor weight and tumor volume. (C) Tumor volume changes during treatment. (D) Quantitative analysis of IHC scores for METTL5 and Ki-67 expression. (E) Representative images of METTL5 and Ki-67 staining. **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; sg, small guide RNA; NC, negative control; IHC, immunohistochemistry.
    Figure Legend Snippet: Inhibition of METTL5 suppresses tumor growth in vivo . (A) Representative images of subcutaneous tumors from the SCC15 cell mouse model. (B) Quantification of tumor weight and tumor volume. (C) Tumor volume changes during treatment. (D) Quantitative analysis of IHC scores for METTL5 and Ki-67 expression. (E) Representative images of METTL5 and Ki-67 staining. **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; sg, small guide RNA; NC, negative control; IHC, immunohistochemistry.

    Techniques Used: Inhibition, In Vivo, Expressing, Staining, Negative Control, Immunohistochemistry

    Knockout of METTL5 selectively inhibits the translation of oncogenic mRNAs. (A) TE scatter plot of METTL5 knockout and control SCC15 cells. (B) Pathway enrichment of TE-downregulated genes. (C) Western blotting confirmed the decreased protein levels of CCND3 in METTL5 knockout SCC15 cells. METTL5, methyltransferase 5, N6-adenosine; TE, translation efficiency; CCND3, cyclin D3; sg, small guide RNA; NC, negative control.
    Figure Legend Snippet: Knockout of METTL5 selectively inhibits the translation of oncogenic mRNAs. (A) TE scatter plot of METTL5 knockout and control SCC15 cells. (B) Pathway enrichment of TE-downregulated genes. (C) Western blotting confirmed the decreased protein levels of CCND3 in METTL5 knockout SCC15 cells. METTL5, methyltransferase 5, N6-adenosine; TE, translation efficiency; CCND3, cyclin D3; sg, small guide RNA; NC, negative control.

    Techniques Used: Knock-Out, Control, Western Blot, Negative Control



    Similar Products

    scc15 cells  (ATCC)
    96
    ATCC scc15 cells
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Scc15 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scc15 cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    scc15 cells - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier
    scc 25 tongue squamous cell carcinoma  (ATCC)
    97
    ATCC scc 25 tongue squamous cell carcinoma
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Scc 25 Tongue Squamous Cell Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scc 25 tongue squamous cell carcinoma/product/ATCC
    Average 97 stars, based on 1 article reviews
    scc 25 tongue squamous cell carcinoma - by Bioz Stars, 2026-04
    97/100 stars
    		  Buy from Supplier
    scc  (ATCC)
    97
    ATCC scc
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Scc, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scc/product/ATCC
    Average 97 stars, based on 1 article reviews
    scc - by Bioz Stars, 2026-04
    97/100 stars
    		  Buy from Supplier
    scc 4  (ATCC)
    96
    ATCC scc 4
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Scc 4, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scc 4/product/ATCC
    Average 96 stars, based on 1 article reviews
    scc 4 - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier
    scc9  (ATCC)
    97
    ATCC scc9
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Scc9, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scc9/product/ATCC
    Average 97 stars, based on 1 article reviews
    scc9 - by Bioz Stars, 2026-04
    97/100 stars
    		  Buy from Supplier
    hypopharyngeal scc cell line fadu  (ATCC)
    99
    ATCC hypopharyngeal scc cell line fadu
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Hypopharyngeal Scc Cell Line Fadu, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hypopharyngeal scc cell line fadu/product/ATCC
    Average 99 stars, based on 1 article reviews
    hypopharyngeal scc cell line fadu - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier
    scc15  (ATCC)
    96
    ATCC scc15
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Scc15, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scc15/product/ATCC
    Average 96 stars, based on 1 article reviews
    scc15 - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier
    atcc crl 1628 293t type culture collection  (ATCC)
    97
    ATCC atcc crl 1628 293t type culture collection
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Atcc Crl 1628 293t Type Culture Collection, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atcc crl 1628 293t type culture collection/product/ATCC
    Average 97 stars, based on 1 article reviews
    atcc crl 1628 293t type culture collection - by Bioz Stars, 2026-04
    97/100 stars
    		  Buy from Supplier
    atcc crl 1629 scc25 atcc  (ATCC)
    97
    ATCC atcc crl 1629 scc25 atcc
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Atcc Crl 1629 Scc25 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atcc crl 1629 scc25 atcc/product/ATCC
    Average 97 stars, based on 1 article reviews
    atcc crl 1629 scc25 atcc - by Bioz Stars, 2026-04
    97/100 stars
    		  Buy from Supplier
    egypt in vitro nanocurcumin scc 4  (ATCC)
    96
    ATCC egypt in vitro nanocurcumin scc 4
    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, <t>SCC15)</t> and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.
    Egypt In Vitro Nanocurcumin Scc 4, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egypt in vitro nanocurcumin scc 4/product/ATCC
    Average 96 stars, based on 1 article reviews
    egypt in vitro nanocurcumin scc 4 - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, SCC15) and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.

    Journal: Oncology Letters

    Article Title: METTL5-mediated m6A modification of 18S rRNA drives oral squamous cell carcinoma progression by enhancing CCND3 translation

    doi: 10.3892/ol.2026.15490

    Figure Lengend Snippet: METTL5 is elevated in HNSCC and is associated with poor prognosis of HNSCC. (A) Comparison of mRNA levels of METTL5 in HNSCC with normal tissues in TCGA-HNSCC dataset. (B) Overall survival of patients between METTL5-high (n=259) and METTL5-low (n=259) groups. (C) METTL5 expression level in normal and HNSCC tissues with different stages of lymph node metastasis. (D) METTL5 expression level in normal tissues and different stages of HNSCC tissues. (E) METTL5 expression level in normal HNSCC tissues and different grades of HNSCC tissues. (F) METTL5 protein level in OSCC(HSC3, SCC15) and HOK cell lines. (G) Representative bands of METTL5 protein expression levels in human OSCC and paired normal tissues measured by western blotting. (H) Semi-quantification of METTL5 protein expression levels in human OSCC and paired normal tissues. *P<0.05, **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; HOK, human normal oral epithelial keratinocyte; HR, hazard ratio; TPM, transcripts per million; N, normal; T, tumor.

    Article Snippet: SCC15 cells were purchased from the American Type Culture Collection (cat. no. CRL-1623).

    Techniques: Comparison, Expressing, Western Blot

    Knockout of METTL5 inhibits the progression of OSCC in vitro . (A) Validation of METTL5 stable knockout in SCC15 cells by western blotting. Results of (B) Cell Counting Kit-8 assay, (C) colony formation assay, (D) Transwell assay and (E) wound healing assay after knockout of METTL5 in SCC15 cells. *P<0.05, **P<0.01; ***P<0.001; ****P<0.0001. METTL5, methyltransferase 5, N6-adenosine; NC, negative control; OSCC, oral squamous cell carcinoma; sg, small guide RNA; NC, negative control; OD, optical density.

    Journal: Oncology Letters

    Article Title: METTL5-mediated m6A modification of 18S rRNA drives oral squamous cell carcinoma progression by enhancing CCND3 translation

    doi: 10.3892/ol.2026.15490

    Figure Lengend Snippet: Knockout of METTL5 inhibits the progression of OSCC in vitro . (A) Validation of METTL5 stable knockout in SCC15 cells by western blotting. Results of (B) Cell Counting Kit-8 assay, (C) colony formation assay, (D) Transwell assay and (E) wound healing assay after knockout of METTL5 in SCC15 cells. *P<0.05, **P<0.01; ***P<0.001; ****P<0.0001. METTL5, methyltransferase 5, N6-adenosine; NC, negative control; OSCC, oral squamous cell carcinoma; sg, small guide RNA; NC, negative control; OD, optical density.

    Article Snippet: SCC15 cells were purchased from the American Type Culture Collection (cat. no. CRL-1623).

    Techniques: Knock-Out, In Vitro, Biomarker Discovery, Western Blot, Cell Counting, Colony Assay, Transwell Assay, Wound Healing Assay, Negative Control

    Overexpression of METTL5 promotes the progression of OSCC. (A) Validation of METTL5 overexpression in SCC15 cells by western blotting. (B) Results of the Cell Counting Kit-8 assay after METTL5 overexpression in SCC15 cells. (C) Statistical results of the Transwell assay after METTL5 overexpression in SCC15 cells. (D) Results of the colony formation assay after knockout of METTL5 in SCC15 cells. **P<0.01. METTL5, methyltransferase 5, N6-adenosine; OSCC, oral squamous cell carcinoma; oe, overexpression; NC, negative control; OD, optical density.

    Journal: Oncology Letters

    Article Title: METTL5-mediated m6A modification of 18S rRNA drives oral squamous cell carcinoma progression by enhancing CCND3 translation

    doi: 10.3892/ol.2026.15490

    Figure Lengend Snippet: Overexpression of METTL5 promotes the progression of OSCC. (A) Validation of METTL5 overexpression in SCC15 cells by western blotting. (B) Results of the Cell Counting Kit-8 assay after METTL5 overexpression in SCC15 cells. (C) Statistical results of the Transwell assay after METTL5 overexpression in SCC15 cells. (D) Results of the colony formation assay after knockout of METTL5 in SCC15 cells. **P<0.01. METTL5, methyltransferase 5, N6-adenosine; OSCC, oral squamous cell carcinoma; oe, overexpression; NC, negative control; OD, optical density.

    Article Snippet: SCC15 cells were purchased from the American Type Culture Collection (cat. no. CRL-1623).

    Techniques: Over Expression, Biomarker Discovery, Western Blot, Cell Counting, Transwell Assay, Colony Assay, Knock-Out, Negative Control

    Inhibition of METTL5 suppresses tumor growth in vivo . (A) Representative images of subcutaneous tumors from the SCC15 cell mouse model. (B) Quantification of tumor weight and tumor volume. (C) Tumor volume changes during treatment. (D) Quantitative analysis of IHC scores for METTL5 and Ki-67 expression. (E) Representative images of METTL5 and Ki-67 staining. **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; sg, small guide RNA; NC, negative control; IHC, immunohistochemistry.

    Journal: Oncology Letters

    Article Title: METTL5-mediated m6A modification of 18S rRNA drives oral squamous cell carcinoma progression by enhancing CCND3 translation

    doi: 10.3892/ol.2026.15490

    Figure Lengend Snippet: Inhibition of METTL5 suppresses tumor growth in vivo . (A) Representative images of subcutaneous tumors from the SCC15 cell mouse model. (B) Quantification of tumor weight and tumor volume. (C) Tumor volume changes during treatment. (D) Quantitative analysis of IHC scores for METTL5 and Ki-67 expression. (E) Representative images of METTL5 and Ki-67 staining. **P<0.01; ***P<0.001. METTL5, methyltransferase 5, N6-adenosine; sg, small guide RNA; NC, negative control; IHC, immunohistochemistry.

    Article Snippet: SCC15 cells were purchased from the American Type Culture Collection (cat. no. CRL-1623).

    Techniques: Inhibition, In Vivo, Expressing, Staining, Negative Control, Immunohistochemistry

    Knockout of METTL5 selectively inhibits the translation of oncogenic mRNAs. (A) TE scatter plot of METTL5 knockout and control SCC15 cells. (B) Pathway enrichment of TE-downregulated genes. (C) Western blotting confirmed the decreased protein levels of CCND3 in METTL5 knockout SCC15 cells. METTL5, methyltransferase 5, N6-adenosine; TE, translation efficiency; CCND3, cyclin D3; sg, small guide RNA; NC, negative control.

    Journal: Oncology Letters

    Article Title: METTL5-mediated m6A modification of 18S rRNA drives oral squamous cell carcinoma progression by enhancing CCND3 translation

    doi: 10.3892/ol.2026.15490

    Figure Lengend Snippet: Knockout of METTL5 selectively inhibits the translation of oncogenic mRNAs. (A) TE scatter plot of METTL5 knockout and control SCC15 cells. (B) Pathway enrichment of TE-downregulated genes. (C) Western blotting confirmed the decreased protein levels of CCND3 in METTL5 knockout SCC15 cells. METTL5, methyltransferase 5, N6-adenosine; TE, translation efficiency; CCND3, cyclin D3; sg, small guide RNA; NC, negative control.

    Article Snippet: SCC15 cells were purchased from the American Type Culture Collection (cat. no. CRL-1623).

    Techniques: Knock-Out, Control, Western Blot, Negative Control